Evidence map›Paper›PMID 37497111›Full record

ArticleFrontiers in pharmacology2023

Development of

Shuang Li, Yanli He, Xuelin Li, Yongxia Xiong, Yan Peng, Chengkun Wang, Linsheng Zhuo, Weifan Jiang, Xianzhou Lu, Zhen Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuang LiSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yanli HeDepartment of Pain Rehabilitation, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xuelin LiSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yongxia XiongSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Yan PengSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Chengkun WangHunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of, South China.
Linsheng ZhuoSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Weifan JiangSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xianzhou LuDepartment of Hepatobiliary Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Zhen WangSchool of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antitumoro-aminobenzamide derivatesalt formationundifferentiated gastric cancerwater solubility

Identifiers

PMID37497111
PMCPMC10368370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.